Blood products giant CSL is pitching for a key role in Australia’s plans to build domestic manufacturing capability for mRNA vaccines, an ambition boosted by new cash in Tuesday’s budget.
Treasurer Josh Frydenberg announced an unspecified amount of funding to help create immediate, large-scale manufacturing of so-called messenger RNA drugs in Australia, technology used in COVID-19 vaccines by companies including Pfizer and Moderna.
Loading...
Tom McIlroy is the Financial Review’s Canberra bureau chief based in the press gallery at Parliament House. He was previously the AFR’s political correspondent. Connect with Tom on Twitter. Email Tom at thomas.mcilroy@afr.com
